The developmental and health benefits of breastfeeding should be considered Patients receiving TRULICITY in combination with an insulin
Do not restart if pancreatitis is confirmed (5.2). Hypoglycemia: When TRULICITY is used with an insulin secretagogue or insulin, consider lowering the dose of
Trulicity (dulaglutide) is not considered insulin, but rather a GLP-1 receptor agonist used to manage type 2 diabetes. Unlike insulin, which directly regulates
Consider automated insulin delivery (like an insulin pump) if appropriate Trulicity (dulaglutide). Possible side effects include nausea
When initiating TRULICITY, consider reducing the dose of concomitantly administered insulin secretagogues (such weight compared to TRULICITY 1.5 mg
When initiating TRULICITY, consider reducing the dosage of concomitantly administered insulin secretagogues. (e.g, sulfonylureas) or insulin to reduce the risk
TRULICITY ; TRULICITY, 0.75MG/0.5ML, Insulin, Canada ; TRULICITY, 1.5MG/0.5ML, Insulin, Canada
insulin, only: as dual therapy with metformin, as triple the Committee considers that TRULICITY (dulaglutide) 0.75 mg and 1.5
Consider other antidiabetic therapies in patients with history of pancreatitis (5.2). Hypoglycemia: When TRULICITY is used with an insulin.
(Now where is the insulin? ;^> ;^> ;^> )